drugset / Trial / NCT00766246
Phase II Avastin Trial for Stage IIIB/IV NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-label, multicenter study in 160 patients in first line treatment and 114 in second line treatment with advanced or metastatic NSCLC (Stage IIIB/IV).
Timeline
- Start
- 2008-10
- Primary completion
- 2012-04
- Completion
- 2012-04
Outcome
Outcome not reported
Stopped (Business): “Withdrawal of funding support”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |